Vidac Pharma Holding (STU:T9G) ROCE % : 0.00% (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Vidac Pharma Holding ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vidac Pharma Holding's annualized ROCE % for the quarter that ended in Jun. 2024 was 0.00%.

Vidac Pharma Holding ROCE % Historical Data

The historical data trend for Vidac Pharma Holding's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vidac Pharma Holding ROCE % Chart

Vidac Pharma Holding Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

Vidac Pharma Holding Semi-Annual Data
	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	-	-	-	-	-

Vidac Pharma Holding ROCE % Calculation

Vidac Pharma Holding's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-1.405	/	( ( (0.054 - 0.914)	+	(0.138 - 1.016) )	/ 2 )
	=	-1.405	/	( (-0.86	+	-0.878)	/ 2 )
	=	-1.405	/	-0.869
	=	161.68 %

Vidac Pharma Holding's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-0.998	/	( ( (0.138 - 1.016)	+	(0.109 - 1.246) )	/ 2 )
	=	-0.998	/	( ( -0.878	+	-1.137 )	/ 2 )
	=	-0.998	/	-1.0075
	=	0 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Vidac Pharma Holding (STU:T9G) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vidac Pharma Holding ROCE % Related Terms

Thank you for viewing the detailed overview of Vidac Pharma Holding's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vidac Pharma Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Wenlock Road, 20-22, London, GBR, N1 7GU

Website

https://www.vidacpharma.com

Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company developing first-in-class oncologic and onco-dermatologic therapies. Its drug, VDA-1102, is at the clinical development stage as an ointment for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL). A second molecule, VDA-1275, with possible application for a wide range of solid tumors.

Vidac Pharma Holding Headlines

No Headlines